When Eli Lilly (LLY) posted strong quarterly results, the stock fell from $750 to $625.65 by August 8. Shareholders fretted about clinical results from its next-generation obesity drug. Its 37.7% Y/Y ...

Ladies and gentlemen, thank you for standing by, and welcome to the Lilly Q2 2025 Earnings Conference Call. [Operator ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

Subtyping is what made precision medicine in cancer a reality. And for successful drug discovery in all its stages, finding ...

Alzheimer's disease is the most common type of dementia. All types of dementia involve a gradual loss of functions such as ...

Findings from a Phase III study highlight the demonstrated action of donanemab-azbt (brand name Kisunla) in slowing the ...

New findings presented at the 2025 Alzheimer’s Association International Conference (AAIC) in Toronto spotlighted the long-term potential of two FDA-approved Alzheimer’s treatments for people with ...

Eli Lilly ( LLY -0.24%) has been a terrific investment in recent years. Thanks to significant clinical progress and outstanding financial results, the company has become the largest healthcare player ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate ...

At AAIC, Lilly highlighted benefits of being able to stop Kisunla, while Eisai made a case for subcutaneous Leqembi, which is ...